Sangamo Therapeutics, Inc.

SGMOQ

None; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001001233

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $59.7M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	short runway, late filer, thin data not computable: dilution, distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Apr 30, 2026 195 days before the rescan; latest periodic filing 10-Q received May 14, 2026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 30, 2026

We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. We believe our zinc finger epigenetic regulators are ideally suited to potentially address devastating neurology disorders and our capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system, or CNS, in preclinical studies.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 13.0						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(31.9%)	(6.6%)		13.0	800	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 93.2						
Twelve-month failure probability	not computable	0.08%				
market price is missing at 2026-03-31						
Altman Z double-prime	(103.36)	(0.35)		95.4	745	2025-12-31
Net debt to EBITDA	not computable	1.82x				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	0.84x	2.95x		91.0	826	2025-12-31
Growth and financing, sleeve percentile 95.0						
Revenue growth, three-year compound	(29.2%)	10.1%		91.5	412	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
NOPAT must exceed $100,000						
Asset growth, three years	(52.6%)	2.2%		98.6	694	2025-12-31
Net share issuance, one year	not computable	2.5%				
prior share count is 26 days earlier						

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.7 months
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-11 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	not computable	(1.9%)	
Distance from 52-week high	not computable	(28.5%)	
EBIT to enterprise value	not computable	(1.6%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.27	
Sales to price	not computable	0.29	
Composite equity issuance, five years	not computable	20.8%	
Relative strength against the sector, log excess return	not computable	(0.19)	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$27.6M
Operating cash flow, four quarters	-$90.3M
Months of runway	3.7
Days since last periodic filing	181 (10-Q received May 14, 2026)
Median daily dollar volume, 63 sessions	n/a

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$122.9M	2025-12-31	2026-03-30	10-K	26-022029
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$97.2M	2025-12-31	2026-03-30	10-K	26-022029
3	assets	us-gaap:Assets	$59.7M	2025-12-31	2026-03-30	10-K	26-022029
4	assets	us-gaap:Assets	$101.6M	2024-12-31	2026-03-30	10-K	26-022029
5	current assets	us-gaap:AssetsCurrent	$35.8M	2025-12-31	2026-03-30	10-K	26-022029
6	current liabilities	us-gaap:LiabilitiesCurrent	$42.5M	2025-12-31	2026-03-30	10-K	26-022029
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.6B	2025-12-31	2026-03-30	10-K	26-022029
8	operating income	us-gaap:OperatingIncomeLoss	-$121.2M	2025-12-31	2026-03-30	10-K	26-022029
9	book equity	us-gaap:StockholdersEquity	-$14.3M	2025-12-31	2026-03-30	10-K	26-022029
10	liabilities	us-gaap:Liabilities	$74.0M	2025-12-31	2026-03-30	10-K	26-022029
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$39.6M	2025-12-31	2026-03-30	10-K	26-022029
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$57.8M	2024-12-31	2026-03-30	10-K	26-022029
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$176.2M	2023-12-31	2025-03-17	10-K	25-013088
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$111.3M	2022-12-31	2024-03-13	10-K	24-010788
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$102,000	2025-12-31	2026-03-30	10-K	26-022029
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$67.1M	2024-12-31	2026-03-30	10-K	26-022029
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$267,000	2024-12-31	2026-03-30	10-K	26-022029
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$224.8M	2023-12-31	2025-03-17	10-K	25-013088
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$21.2M	2023-12-31	2025-03-17	10-K	25-013088
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$223.6M	2022-12-31	2024-03-13	10-K	24-010788
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$20.2M	2022-12-31	2024-03-13	10-K	24-010788
22	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$4.0M	2025-12-31	2026-03-30	10-K	26-022029
23	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$123.5M	2025-12-31	2026-03-30	10-K	26-022029
24	income tax	us-gaap:IncomeTaxExpenseBenefit	-$568,000	2025-12-31	2026-03-30	10-K	26-022029
25	current assets	us-gaap:AssetsCurrent	$51.7M	2024-12-31	2026-03-30	10-K	26-022029
26	current liabilities	us-gaap:LiabilitiesCurrent	$45.8M	2024-12-31	2026-03-30	10-K	26-022029
27	assets	us-gaap:Assets	$165.3M	2023-12-31	2025-03-17	10-K	25-013088
28	assets	us-gaap:Assets	$562.5M	2022-12-31	2024-03-13	10-K	24-010788
29	shares outstanding	dei:EntityCommonStockSharesOutstanding	414,275,509	2026-04-20	2026-04-30	10-K/A	26-028524
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	414,274,017	2026-03-25	2026-03-30	10-K	26-022029

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.